



Antibiotic Resistance in *Acinetobacter* and Associated Treatment Strategies

Guest Editors:

Dr. Steven E. Fiester

1. Department of Chemistry, Furman University, Greenville, SC 29613, USA
2. Department of Pathology, Prisma Health, School of Health Science Research, Clemson University, Clemson, SC 29634, USA
3. Dorn Research Institute, Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC 29209, USA

Dr. William Penwell

Department of Biology and Marine Science, Jacksonville University, Jacksonville, FL, USA

Deadline for manuscript submissions:

30 November 2024

Message from the Guest Editors

Dear Colleagues,

Acinetobacter infections cause a substantial burden on public health, with the Centers for Disease Control and Prevention specifically classifying carbapenem-resistant *Acinetobacter* as an urgent threat to public health with 8500 cases annually, 700 deaths, and USD 281 million in associated healthcare costs in the United States alone. These data coupled with the sparsity of information elucidating the pathophysiology of *Acinetobacter*, the lack of novel antibiotics in the developmental pipeline to treat *Acinetobacter* infections, the continued occurrence of multidrug-, extensively drug-, or even pandrug-resistant isolates from clinical settings and the association of *Acinetobacter* secondary infection in SARS-CoV-2 patients constitute a public health crisis warranting immediate attention. This Special Issue therefore particularly encourages submissions that describe resistance mechanisms of *Acinetobacter* that allow this human pathogen to resist destruction by the immune system, persist in the clinical environment due to resistance to disinfectants, and survive clinical treatment due to antibiotic resistance.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi